Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes

Fecha de publicación:

Autores de CIPF

Participantes ajenos a CIPF

  • Andreu-Fernandez, V
  • Genoves, A
  • Todt, F
  • Lauterwasser, J
  • Funk, K
  • Jahreis, G
  • Mingarro, I
  • Edlich, F

Grupos de Investigación

Abstract

The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apoptosis regulator) can commit cells to apoptosis via outer mitochondrial membrane permeabilization. Bax activity is controlled in healthy cells by prosurvival Bcl-2 proteins. C-terminal Bax transmembrane domain interactions were implicated recently in Bax pore formation. Here, we show that the isolated transmembrane domains of Bax, Bcl-xL (B-cell lymphoma-extra large), and Bcl-2 can mediate interactions between Bax and prosurvival proteins inside the membrane in the absence of apoptotic stimuli. Bcl-2 protein transmembrane domains specifically homooligomerize and heterooligomerize in bacterial and mitochondrial membranes. Their interactions participate in the regulation of Bcl-2 proteins, thus modulating apoptotic activity. Our results suggest that interactions between the transmembrane domains of Bax and antiapoptotic Bcl-2 proteins represent a previously unappreciated level of apoptosis regulation.

Datos de la publicación

ISSN/ISSNe:
0027-8424, 1091-6490

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA  NATL ACAD SCIENCES

Tipo:
Article
Páginas:
310-315
PubMed:
28028215

Citas Recibidas en Web of Science: 81

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • apoptosis; Bcl-2; mitochondria; oligomerization; transmembrane

Campos de Estudio

Proyectos asociados

Exploiting Protein Complexes that induce Cell-death

Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD

COMMISSION OF EUROPEAN COMMUNITIES . 2016

Red de Transtornos Adictivos

Investigador Principal: CONSUELO GUERRI SIRERA

INSTITUTO DE SALUD CARLOS III . 2017

El cebado mitocondrial como herramienta para desarrollar una medicina personalizada contra el cáncer de endometrio

Investigador Principal: MÓNICA SANCHO MEDINA

2016

Compartir